Recap: Johnson & Johnson Q2 Earnings

Shares of Johnson & Johnson JNJ moved higher by 0.1% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share fell 35.27% year over year to $1.67, which beat the estimate of $1.48.

Revenue of $18,336,000,000 decreased by 10.83% year over year, which beat the estimate of $17,500,000,000.

Guidance

Q3 EPS expected between $7.75 and $7.95.

The upcoming fiscal year's revenue expected to be between $79,900,000,000 and $81,400,000,000.

Conference Call Details

Date: Jul 16, 2020

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/y8jhbf4v

Recent Stock Performance

52-week high: $157.00

Company's 52-week low was at $109.16

Price action over last quarter: Up 0.77%

Company Overview

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total revenue is generated in the United States.